Literature DB >> 25918438

Ovarian cancer: involvement of the matrix metalloproteinases.

Linah Al-Alem1, Thomas E Curry2.   

Abstract

Ovarian cancer is the leading cause of death from gynecologic malignancies. One of the reasons for the high mortality rate associated with ovarian cancer is its late diagnosis, which often occurs after the cancer has metastasized throughout the peritoneal cavity. Cancer metastasis is facilitated by the remodeling of the extracellular tumor matrix by a family of proteolytic enzymes known as the matrix metalloproteinases (MMPs). There are 23 members of the MMP family, many of which have been reported to be associated with ovarian cancer. In the current paradigm, ovarian tumor cells and the surrounding stromal cells stimulate the synthesis and/or activation of various MMPs to aid in tumor growth, invasion, and eventual metastasis. The present review sheds light on the different MMPs in the various types of ovarian cancer and on their impact on the progression of this gynecologic malignancy.
© 2015 Society for Reproduction and Fertility.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25918438      PMCID: PMC4955511          DOI: 10.1530/REP-14-0546

Source DB:  PubMed          Journal:  Reproduction        ISSN: 1470-1626            Impact factor:   3.906


  94 in total

1.  An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.

Authors:  Ivo Meinhold-Heerlein; Dirk Bauerschlag; Yingyao Zhou; Lisa M Sapinoso; Keith Ching; Henry Frierson; Karen Bräutigam; Jalid Sehouli; Elmar Stickeler; Dominique Könsgen; Felix Hilpert; Constantin S von Kaisenberg; Jacobus Pfisterer; Thomas Bauknecht; Walter Jonat; Norbert Arnold; Garret M Hampton
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

2.  Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer.

Authors:  S Sillanpää; M Anttila; K Voutilainen; K Ropponen; T Turpeenniemi-Hujanen; U Puistola; R Tammi; M Tammi; R Sironen; S Saarikoski; V-M Kosma
Journal:  Gynecol Oncol       Date:  2006-10-10       Impact factor: 5.482

Review 3.  The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis.

Authors:  A John; G Tuszynski
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

4.  Survival and prognostic factors in patients with ovarian cancer.

Authors:  Solveig Tingulstad; Finn Egil Skjeldestad; Tore B Halvorsen; Bjørn Hagen
Journal:  Obstet Gynecol       Date:  2003-05       Impact factor: 7.661

5.  Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.

Authors:  Dorina Belotti; Paola Paganoni; Luigi Manenti; Angela Garofalo; Sergio Marchini; Giulia Taraboletti; Raffaella Giavazzi
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

6.  Matrix metalloproteinase-8 promoter gene polymorphisms in Mexican women with ovarian cancer.

Authors:  Fabian Arechavaleta-Velasco; Rocio Cuevas-Antonio; Pablo Dominguez-Lopez; Isaias Estrada-Moscoso; Fazlollah Shahram Imani-Razavi; Moises Zeferino-Toquero; Laura Diaz-Cueto
Journal:  Med Oncol       Date:  2014-07-18       Impact factor: 3.064

7.  Expression of matrix metalloproteinase-26 in multiple human cancer tissues and smooth muscle cells.

Authors:  Yun-Ge Zhao; Ai-Zhen Xiao; Jian Ni; Yan-Gao Man; Qing-Xiang Amy Sang
Journal:  Ai Zheng       Date:  2009-11

8.  The functional polymorphisms on promoter region of matrix metalloproteinase-12, -13 genes may alter the risk of epithelial ovarian carcinoma in Chinese.

Authors:  Yan Li; Jing-Hui Jia; Shan Kang; Xiao-Juan Zhang; Jian Zhao; Na Wang; Rong-Miao Zhou; Dong-Lan Sun; Ya-Nan Duan; Dong-Jie Wang
Journal:  Int J Gynecol Cancer       Date:  2009-01       Impact factor: 3.437

9.  Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP.

Authors:  Farideh Sabeh; Ichiro Ota; Kenn Holmbeck; Henning Birkedal-Hansen; Paul Soloway; Milagros Balbin; Carlos Lopez-Otin; Steven Shapiro; Masaki Inada; Stephen Krane; Edward Allen; Duane Chung; Stephen J Weiss
Journal:  J Cell Biol       Date:  2004-11-22       Impact factor: 10.539

Review 10.  Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling.

Authors:  Qishan Chen; Min Jin; Feng Yang; Jianhua Zhu; Qingzhong Xiao; Li Zhang
Journal:  Mediators Inflamm       Date:  2013-06-12       Impact factor: 4.711

View more
  43 in total

1.  MicroRNA-192 inhibits the proliferation, migration and invasion of osteosarcoma cells and promotes apoptosis by targeting matrix metalloproteinase-11.

Authors:  Guowei Shang; Yang Mi; Yingwu Mei; Guanghui Wang; Yadong Wang; Xinjie Li; Yisheng Wang; Yuebai Li; Guoqiang Zhao
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

2.  [Expressions of OCT4, Notch1 and DLL4 and their clinical implications in epithelial ovarian cancer].

Authors:  Lan Yu; Yun-Jie Jiao; Lei Zhou; Wen-Qing Song; Shi-Wu Wu; Dan-Na Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-04-20

3.  Fluorescence and Multiphoton Imaging for Tissue Characterization of a Model of Postmenopausal Ovarian Cancer.

Authors:  Travis W Sawyer; Jennifer W Koevary; Caitlin C Howard; Olivia J Austin; Photini F S Rice; Gabrielle V Hutchens; Setsuko K Chambers; Denise C Connolly; Jennifer K Barton
Journal:  Lasers Surg Med       Date:  2020-04-20       Impact factor: 4.025

Review 4.  Matrix Metalloproteinases in Chemoresistance: Regulatory Roles, Molecular Interactions, and Potential Inhibitors.

Authors:  Bernadette Xin Jie Tune; Maw Shin Sim; Chit Laa Poh; Rhanye Mac Guad; Choy Ker Woon; Iswar Hazarika; Anju Das; Subash C B Gopinath; Mariappan Rajan; Mahendran Sekar; Vetriselvan Subramaniyan; Neeraj Kumar Fuloria; Shivkanya Fuloria; Kalaivani Batumalaie; Yuan Seng Wu
Journal:  J Oncol       Date:  2022-05-09       Impact factor: 4.501

5.  Overexpression of ERCC6L correlates with poor prognosis and confers malignant phenotypes of lung adenocarcinoma.

Authors:  Xiaoyue Huang; Lingyu Jiang; Sufang Lu; Mingqing Yuan; Hui Lin; Baijun Li; Zhaoke Wen; Yonglong Zhong
Journal:  Oncol Rep       Date:  2022-06-03       Impact factor: 4.136

Review 6.  Developmental Programming of Ovarian Functions and Dysfunctions.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  Vitam Horm       Date:  2018-02-22       Impact factor: 3.421

7.  Genes associated with bowel metastases in ovarian cancer.

Authors:  Andrea Mariani; Chen Wang; Ann L Oberg; Shaun M Riska; Michelle Torres; Joseph Kumka; Francesco Multinu; Gunisha Sagar; Debarshi Roy; Deok-Beom Jung; Qing Zhang; Tommaso Grassi; Daniel W Visscher; Vatsal P Patel; Ling Jin; Julie K Staub; William A Cliby; Saravut J Weroha; Kimberly R Kalli; Lynn C Hartmann; Scott H Kaufmann; Ellen L Goode; Viji Shridhar
Journal:  Gynecol Oncol       Date:  2019-06-14       Impact factor: 5.482

Review 8.  The Mesothelial Origin of Carcinoma Associated-Fibroblasts in Peritoneal Metastasis.

Authors:  Angela Rynne-Vidal; José Antonio Jiménez-Heffernan; Concepción Fernández-Chacón; Manuel López-Cabrera; Pilar Sandoval
Journal:  Cancers (Basel)       Date:  2015-09-29       Impact factor: 6.639

9.  Relevance of HLA-DP/DQ and ICAM-1 SNPs among Ovarian Cancer Patients.

Authors:  Amany A Ghazy; Nour M El-Etreby
Journal:  Front Immunol       Date:  2016-05-24       Impact factor: 7.561

10.  The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer.

Authors:  Anuj Suri; Xiugui Sheng; Kevin M Schuler; Yan Zhong; Xiaoyun Han; Hannah M Jones; Paola A Gehrig; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Oncotarget       Date:  2016-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.